Pharmacological Properties of DOV 315,090, an ocinaplon metabolite
Open accessAbstract
Background: Compounds targeting the benzodiazepine binding site of the GABA A-R are widely prescribed for the treatment of anxiety disorders, epilepsy, and insomnia as well as for pre-anesthetic sedation and muscle relaxation. It has been hypothesized that these various pharmacological effects are mediated by different GABA A-R subtypes. If this hypothesis is correct, then it may be possible to develop compounds targeting particular GABA A-R subtypes as, for example, selective anxiolytics with a diminished side effect profile. The pyrazolo[1,5-a]-pyrimidine ocinaplon is anxioselective in both preclinical studies and in patients with generalized anxiety disorder, but does not exhibit the selectivity between α 1/α 2-containing receptors for an anxioselective that is predicted by studies using transgenic mice. Results: We hypothesized that the pharmacological properties of ocinaplon in vivo might be influenced by an active biotransformation product with greater selectivity for the α 2 subunit relative to α 1. One hour after administration of ocinaplon, the plasma concentration of its primary biotransformation product, DOV 315,090, is 38% of the parent compound. The pharmacological properties of DOV 315,090 were assessed using radioligand binding studies and two-electrode voltage clamp electrophysiology. We report that DOV 315,090 possesses modulatory activity at GABA A-Rs, but that its selectivity profile is similar to that of ocinaplon. Conclusion: These findings imply that DOV 315,090 could contribute to the action of ocinaplon in vivo, but that the anxioselective properties of ocinaplon cannot be readily explained by a subtype selective effect/action of DOV 315,090. Further inquiry is required to identify the extent to which different subtypes are involved in the anxiolytic and other pharmacological effects of GABA A-R modulators.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GABA-gated currents increase hyperbolically with increasing diazepam concentrations in cellular models, including recombinant human GABA-A receptors.
“GABA-gated currents increase hyperbolically with increasing diazepam concentrations in cellular models (Berezhnoy et al., 2008; Wongsamitkul et al., 2017), including recombinant human GABA-A receptors (Atack, 2009) (Figure 3a).”
From Pharmacological principles for safe benzodiazepine and Z-drug dose reduction (2026) · cites this paper as Berezhnoy et al., 2008
The Methods fit diazepam potentiation of GABA-gated currents to a hyperbolic concentration-response equation, supporting the claim for the tested cellular model. The Methods and Figure 4 caption also say potentiation declined above 3 μM, so the increase does not hold across all increasing concentrations. The recombinant human receptor example is attributed to Atack (2009), not to this paper. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126 · see citing works
Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family
Schofield, P. R., Darlison, M. G., Fujita, N., Burt, D. R., Stephenson, F. A., Rodriguez, H., Rhee, L. M., Ramachandran, J., Reale, V., Glencorse, T. A., et al. (1987) · Nature · doi:10.1038/328221a0 · Cited by 1,622 · see citing works
Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.
Sieghart, W. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06840-1 · Cited by 1,301 · see citing works
Barnard, E. A., Skolnick, P., Olsen, R. W., Möhler, H., Sieghart, W., Biggio, G., Bræstrup, C., Bateson, A. N., & Langer, S. Z. (1998) · PubMed · Cited by 1,204 · see citing works
Self-citationBenzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172 · see citing works
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946 · see citing works
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944 · see citing works
Subunit Composition, Distribution and Function of GABA-A Receptor Subtypes
Sieghart, W., & Sperk, G. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023393507 · Cited by 914 · see citing works
Barnard, E. A., Skolnick, P., Olsen, R. W., Möhler, H., Sieghart, W., Biggio, G., Bræstrup, C., Bateson, A. N., & Langer, S. Z. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01363-2 · Cited by 711 · see citing works
Self-citationCollinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628 · see citing works
Cerebellar GABAA receptor selective for a behavioural alcohol antagonist
Lüddens, H., Pritchett, D. B., Köhler, M. G., Killisch, I., KEINÄNEN, K. P., Monyer, H., Sprengel, R., & Seeburg, P. H. (1990) · Nature · doi:10.1038/346648a0 · Cited by 538 · see citing works
Rudolph, U., & Möhler, H. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121429 · Cited by 518 · see citing works
The diversity of GABAA receptors
Hevers, W., & Lüddens, H. (1998) · Molecular Neurobiology · doi:10.1007/bf02741459 · Cited by 482 · see citing works
From ion currents to genomic analysis: Recent advances in GABAA receptor research
Rabow, L. E., Russek, S. J., & Farb, D. H. (1995) · Synapse · doi:10.1002/syn.890210302 · Cited by 469 · see citing works
Self-citationGABA A receptor subtypes: from pharmacology to molecular biology
Burt, D. R., & Kamatchi, G. L. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.14.1661244 · Cited by 425 · see citing works
A gamma-aminobutyric acid/benzodiazepine receptor complex of bovine cerebral cortex.
Sigel, E., Stephenson, F. A., Mamalaki, C., & Barnard, E. A. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32319-6 · Cited by 367 · see citing works
The mechanism of the calcium signal and correlation with histamine release in 2H3 cells.
Beaven, M. A., Rogers, J., Moore, J. P., Hesketh, T. R., Smith, G. A., & Metcalfe, J. C. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39847-2 · Cited by 351 · see citing works
GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery?
Whiting, P. J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02703-x · Cited by 325 · see citing works
θ, a novel γ-aminobutyric acid type A receptor subunit
Bonnert, T. P., McKernan, R. M., Farrar, S. J., Bourdellès, B. L., HEAVENS, R. P., Smith, D. W., Hewson, L., Rigby, M. R., SIRINATHSINGHJI, D. J. S., Brown, N. A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9891 · Cited by 303 · see citing works
Dias, R., Sheppard, W. F. A., Fradley, R. L., Garrett, E. M., Stanley, J. L., Tye, S. J., Goodacre, S., Lincoln, R. J., Cook, S. M., Conley, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1166-05.2005 · Cited by 247 · see citing works
An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition
Dawson, G. R., Maubach, K. A., Collinson, N., Cobain, M., Everitt, B. J., MacLeod, A. M., Choudhury, H. I., McDonald, L. M., Pillai, G., Rycroft, W., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092320 · Cited by 241 · see citing works
Rowlett, J. K., Platt, D. M., Lelas, S., Atack, J. R., & Dawson, G. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405621102 · Cited by 212 · see citing works
Sigel, E., & Barnard, E. A. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39860-5 · Cited by 209 · see citing works
Atack, J. R., Wafford, K. A., Tye, S. J., Cook, S. M., Sohal, B., Pike, A., Sur, C., Melillo, D., Bristow, L., Bromidge, F., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089920 · Cited by 188 · see citing works
Dundar, Y., Dodd, S. R., Strobl, J., Boland, A., Dickson, R., & Walley, T. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.594 · Cited by 168 · see citing works
Mapping the Agonist Binding Site of the GABAAReceptor: Evidence for a β-Strand
Boileau, A. J., Evers, A. R., Davis, A. F., & Czajkowski, C. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-12-04847.1999 · Cited by 148 · see citing works
Goodacre, S. C., Street, L. J., Hallett, D. J., Crawforth, J. M., Kelly, S., Owens, A. P., Blackaby, W., Lewis, R. T., Stanley, J. L., Smith, A. J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm051065l · Cited by 136 · see citing works
Anxiogenic properties of an inverse agonist selective for α3 subunit‐containing GABAA receptors
Atack, J. R., Hutson, P. H., Collinson, N., Marshall, G. R., Bentley, G., Moyes, C. R., Cook, S. M., Collins, I., Wafford, K. A., McKernan, R. M., et al. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706056 · Cited by 135 · see citing works
Selective anxiolysis produced by ocinaplon, a GABA A receptor modulator
LIPPA, A. S., Czobor, P., Stark, J., Beer, B., Kostakis, E., Gravielle, M. C., Bandyopadhyay, S., Russek, S. J., Gibbs, T. T., Farb, D. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502579102 · Cited by 125 · see citing works
Self-citationMorris, H. V., Dawson, G. R., Reynolds, D. S., Atack, J. R., & Stephens, D. N. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04775.x · Cited by 110 · see citing works
Chambers, M. S., Atack, J. R., Carling, R. W., Collinson, N., Cook, S. M., Dawson, G. R., Ferris, P., Hobbs, S. C., O'Connor, D. V., Marshall, G. R., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040863t · Cited by 109 · see citing works
de Haas, S. L., de Visser, S. J., Post, J. P. V. D., Schoemaker, R. C., Dyck, K. V., Murphy, M. G., Smet, M. D., Vessey, L. K., Ramakrishnan, R., Xue, L., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107082108 · Cited by 104 · see citing works
Boileau, A. J., Kucken, A. M., Evers, A. R., & Czajkowski, C. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.2.295 · Cited by 88 · see citing works
de Haas, S. L., de Visser, S. J., van der Post, J. P., de Smet, M., Schoemaker, R. C., Rijnbeek, B., Cohen, A. F., Vega, J. M., Agrawal, N. G. B., Goel, T. V., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072343 · Cited by 84 · see citing works
Yang, W., Drewe, J. A., & Lan, N. C. (1995) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(95)90072-1 · Cited by 70 · see citing works
Teissére, J. A., & Czajkowski, C. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-14-04977.2001 · Cited by 59 · see citing works
Griebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Decobert, M., Françon, D., Avenet, P., Depoortere, H., Tan, S., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29437-4 · Cited by 59 · see citing works
Carling, R. W., Madin, A., Guiblin, A., Russell, M. G. N., Moore, K. W., Mitchinson, A., Sohal, B., Pike, A. J., Cook, S. M., Ragan, I., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058034a · Cited by 54 · see citing works
Russell, M. G. N., Carling, R. W., Street, L. J., Hallett, D. J., Goodacre, S. C., Mezzogori, E., Reader, M., Cook, S. M., Bromidge, F. A., Newman, R. J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051200u · Cited by 47 · see citing works
Handbook of Contemporary Neuropharmacology
(2006) · Wiley eBooks · doi:10.1002/9780470101001 · Cited by 46 · see citing works
Savić, M. M., Obradovic, D. I., Ugrešić, N. D., Cook, J. M., Yin, W., & Bokonjić, D. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.07.013 · Cited by 45 · see citing works
Popik, P., Kostakis, E., Krawczyk, M., Nowak, G., Szewczyk, B., Krieter, P. A., Chen, Z., Russek, S. J., Gibbs, T. T., Farb, D. H., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.107201 · Cited by 41 · see citing works
Self-citationSavić, M. M., Obradovic, D. I., Ugrešić, N. D., COOK, J., YIN, W., & Bokonjić, D. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.09.011 · Cited by 32 · see citing works
Handbook of Contemporary Neuropharmacology
Bleakman, D., Alt, A., Lodge, D., Monaghan, D., Jane, D. E., & Nisenbaum, E. (2007) · Cited by 31 · see citing works
A Pyridazine Series of α2/α3 Subtype Selective GABAA Agonists for the Treatment of Anxiety
Lewis, R. T., Blackaby, W., Blackburn, T. J., Jennings, A. S. R., Pike, A. J., Wilson, R. A., Hallett, D. J., Cook, S. M., Ferris, P., Marshall, G. R., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051144x · Cited by 30 · see citing works
Handbook of Contemporary Neuropharmacology
Brown, W. A., Solomon, D. A., & Khan, A. O. (2007) · JAMA · doi:10.1001/jama.298.22.2682 · Cited by 27 · see citing works
Paronis, C. A., Cox, E. D., Cook, J. R., & Bergman, J. (2001) · Psychopharmacology · doi:10.1007/s002130100754 · Cited by 22 · see citing works
Jennings, A. S. R., Lewis, R. T., Russell, M. G. N., Hallett, D. J., Street, L. J., Castro, J. L., Atack, J. R., Cook, S. M., Lincoln, R. J., Stanley, J. L., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.12.044 · Cited by 19 · see citing works
Pharmacology of the GABAAReceptor
Berezhnoy, D., Gravielle, M. C., & Farb, D. H. (2007) · doi:10.1002/9780470101001.hcn012 · Cited by 12 · see citing works
Self-citation
Flagged first, then by citations
2 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Sigel E Stephenson FA Mamalaki C Barnard EA A γ-aminobutyric acid/benzodiapzepine receptor complex from bovine cerebral cortex J Biol Chem 1983 258 6965 6971 6304068
- Burt DR Kamatchi GL GABAA receptor subtypes: From pharmacology to molecular biology FASEB J 1991 5 2916 2923 1661244
Cited by
Sorted by citations
Sieghart, W., & Savić, M. M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014449 · Cited by 211 · see citing works
Atack, J. R., Hallett, D. J., Tye, S. J., Wafford, K. A., Ryan, C. N., Bohorquez, S. M. S., Eng, W., Gibson, R., Burns, H. D., Dawson, G., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109354928 · Cited by 63 · see citing works
Atack, J. R., Wafford, K. A., Street, L. O. N. D. O. N. G., Dawson, G., Tye, S. J., Laere, K. V., Bormans, G. M., Bohorquez, S. M. S., Lepeleire, I. D., de Hoon, J., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109354927 · Cited by 60 · see citing works
Atack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52 · see citing works
Savić, M. M., Majumder, S., Huang, S., Edwankar, R. V., Furtmüller, R., Joksimovic, S. M., Clayton, T., Ramerstorfer, J., Milinković, M. M., Roth, B. L., et al. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.01.004 · Cited by 51 · see citing works
Kostakis, E., Smith, C. C., Jang, M., Martin, S. C., Richards, K. G., Russek, S. J., Gibbs, T. T., & Farb, D. H. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.085696 · Cited by 39 · see citing works
Self-citationParticle uptake efficiency is significantly affected by type of capping agent and cell line
Zhang, F., Durham, P. G., Sayes, C. M., Lau, B. L. T., & Bruce, E. D. (2015) · Journal of Applied Toxicology · doi:10.1002/jat.3138 · Cited by 19 · see citing works
Nothdurfter, C., Rupprecht, R., & Rammes, G. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799078748 · Cited by 19 · see citing works
Atack, J. R. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0226-6_2 · Cited by 18 · see citing works
Chagraoui, A., Skiba, M., Thuillez, C., & Thibaut, F. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.08.001 · Cited by 16 · see citing works
Petrov, A. A., Kasatochkin, A. N., Emelina, E. E., Nelyubina, Y. V., & Antipin, M. Y. (2009) · Russian Journal of Organic Chemistry · doi:10.1134/s1070428009090139 · Cited by 15 · see citing works
Study of regioselectivity of reactions between 3(5)-aminopyrazoles and 2-acetylcycloalkanones
Petrov, A. A., Kasatochkin, A. N., & Emelina, E. E. (2012) · Russian Journal of Organic Chemistry · doi:10.1134/s1070428012080131 · Cited by 11 · see citing works
Medicinal Chemistry of Pyrazolopyrimidine Scaffolds Substituted with Different Heterocyclic Nuclei
Elgemeie, G. H., Azzam, R. A., Zaghary, W. A., Khedr, M. A., & Elsherif, G. E. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612829666221102162000 · Cited by 10 · see citing works
Gurrell, R., Whitlock, M., Wei, H., Shen, Z., & Ogden, A. G. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.912 · Cited by 10 · see citing works
Burkat, P. M. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2071 · Cited by 5 · see citing works
Singh, S., Singh, K., & Tahlan, S. (2024) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-024-03095-7 · Cited by 4 · see citing works
Pharmacological principles for safe benzodiazepine and Z-drug dose reduction
Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026) · Psychological Medicine · doi:10.1017/s0033291726104887
“GABA-gated currents increase hyperbolically with increasing diazepam concentrations in cellular models (Berezhnoy et al., 2008; Wongsamitkul et al., 2017), including recombinant human GABA-A receptors (Atack, 2009) (Figure 3a).”
Safe Deprescribing of Benzodiazepines and Z‐drugs
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg003
- Authors
- Berezhnoy, D., Gravielle, M. C., Downing, S., Kostakis, E., Basile, A. S., Skolnick, P., Gibbs, T. T., & Farb, D. H.
- Affiliations
- Boston University (US)
- Corresponding author
- Farb, David H
- Venue
- BMC Pharmacology
- Published
- 2008-06-13
- Volume
- 8
- Issue
- 1
- Pages
- 11-11
- ISSN
- 1471-2210 (ISSN-L)
- PMC
- PMC2529273
- OpenAlex
- W2033853536
- Cited by
- 18
- References
- 51
- Citations by year
- 2026: 1 · 2024: 2 · 2022: 2 · 2021: 1 · 2018: 1 · 2016: 1 · 2015: 1 · 2013: 1 · 2012: 2
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- BMC Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OpenBU (Boston University) (submittedVersion, other-oa)
- Funders
- Menarini Group
- National Institute of Mental Health (R01MH049469)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GABAA receptor, benzodiazepine binding site, GABAA receptor subtypes, biotransformation products, anxiolytic effects, pyrazolo[1,5-a]pyrimidines, GABA-A receptor modulators
- MeSH terms
- Animals, Cell Line, Cyclic N-Oxides, Diazepam, Humans, Oocytes, Pyrimidines, Receptors, GABA-A, Anti-Anxiety Agents, Xenopus laevis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
